For the quarter ending 2025-09-30, AWHL had $2,264K increase in cash & cash equivalents over the period. -$220K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -4,892 | -4,519 |
| Non-cash lease expense | 158 | 122 |
| Depreciation and amortization | 50 | 24 |
| Stock-based compensation expense | 36 | 119 |
| Change in fair value of warrant liabilities | 4,309 | -297 |
| Change in fair value of convertible notes | -170 | -170 |
| Loss upon issuance of convertible notes carried at fair value | 1,198 | 1,198 |
| Loss on impairment and disposal of property and equipment | 0 | -1 |
| Accounts receivable | 39 | 288 |
| Prepaid expenses and other assets | -245 | -426 |
| Inventories | 9 | -53 |
| Accounts payable | 68 | -430 |
| Accrued liabilities | 138 | -616 |
| Other liabilities | -154 | -459 |
| Net cash used in operating activities | -212 | -4,836 |
| Purchase of property and equipment | 8 | 0 |
| Purchase of intangible assets | 385 | - |
| Net cash used in investing activities | -393 | 0 |
| Proceeds from issuance of common stock-Two Thousand Twenty Four Direct Offering | - | 0 |
| Principal repayment of decd loan | 58 | 116 |
| Proceeds from issuance of common stock-Two Thousand Twenty Four At The Market Offering Agreement | 3,484 | 3,484 |
| Payment of stock issuance costs-Two Thousand Twenty Four At The Market Offering Agreement | 147 | - |
| Proceeds from issuance of common stock-Two Thousand Twenty Five Private Placement Offering | 2,949 | - |
| Payment of stock issuance costs-Two Thousand Twenty Five Private Placement Offering | 134 | - |
| Proceeds from issuance of common stock-Equity Line Of Credit Agreement | - | 0 |
| Proceeds from issuance of common stock from exercise of warrants | 112 | - |
| Payment of stock issuance costs-Two Thousand Twenty Four Direct Offering | - | 0 |
| Proceeds from convertible notes | 0 | 1,366 |
| Payment of stock issuance costs | - | 147 |
| Proceeds from equity line of credit | 0 | 25 |
| Net cash provided by financing activities | 2,869 | 4,612 |
| Net decrease in cash, cash equivalents and restricted cash | 2,264 | -224 |
| Cash and cash equivalents at beginning of period | 1,769 | - |
| Cash and cash equivalents at end of period | 3,809 | - |
Aspira Women's Health Inc. (AWHL)
Aspira Women's Health Inc. (AWHL)